Tumor infiltrating lymphocyte therapy (CAR-T (Shanghai) Cell Biotechnology)

肿瘤浸润淋巴细胞（卡替（上海）生物技术有限公司）

Report date: 2024/01/02 20:03:52

Base Information

Drug NameTumor infiltrating lymphocyte therapy (CAR-T (Shanghai) Cell Biotechnology)
Drug Alias NameAutologous TILs (CAR-T (Shanghai) Cell Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionLymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesCar-T (Shanghai) Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCar-T (Shanghai) Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A